SLC5A2 and chronic kidney disease: SGLT2 inhibitors have been linked to a deceleration of chronic kidney disease (CKD) advancement, as demonstrated by a decrease in the rate at which blood creatinine doubles and the necessity for renal replacement therapy [18].